In particular, the derivative N-[2-(dimethylamino)ethyl]−2,3-dimethyl-4-oxo-4H-pyrido[1,2-a]thieno[2,3-d]pyrimidine-9-carboxamide (PTP) showed strong anti-tumor effects against human CRC cells by activating p53. This evidence concerns the gene TP53 and neoplasm.